Among the comutations of NPM1mut AML, TET2(+) was identified as an independent factor predicting lower cCR rate and inferior EFS in the NPM1mut/FLT3‐ITD(−) group, consistent with other results.28, 29. This evidence concerns the gene TET2 and acute myeloid leukemia.